Small-molecule inhibitors of HIV-induced receptor downmodulation

HIV 诱导的受体下调的小分子抑制剂

基本信息

  • 批准号:
    8052156
  • 负责人:
  • 金额:
    $ 35.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-05-01 至 2012-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Multiple lines of evidence suggest that down-modulation of the viral receptor in HIV- infected cells is an essential function modulating pathogenesis in vivo. We have previously performed proof-of-concept studies demonstrating that interference with this function results in the production of non-infectious particles unable to replicate in permissive cells. Here we propose to screen a library of small molecules to identify inhibitors of CD4 down-modulation. We will use a simple screening assay that recapitulates physiological conditions and use natural target cells of infection. We propose the following aims: (1) to optimize an assay for CD4 down-modulation in HIV-infected PBMC; (2) to screen a library of 20,000 drug-like compounds, and; (3) to validate and characterize the potency, cytotoxicity and specificity of hits. Studies will be implemented to optimize screening conditions, reduce assay-to-assay variability and perform statistical analysis to set thresholds for hit identification. False positives and artifacts will be discriminated in secondary assays, and true hit compounds will be prioritized based on potency, specificity, and lack of cytotoxicity. Preliminary studies will be performed to validate the mechanism of action and test the compounds antiviral activity with laboratory adapted HIV strains and primary isolates. Success in this Phase I application is defined as the milestone identification of one or more bona fide lead series of drug-like compounds with IC50s below 5 5M in HIV replication assays and minimal cytotoxicity (CC50 10-fold greater than IC50). Lead compounds with these profiles will be optimized for potency, specificity and bioavailability in a Phase II project aimed at advancing the preclinical development of these compounds to support human trials. These studies will constitute the foundation of a drug discovery program that may result in the characterization of first-in-class drugs of a novel family of antiretrovirals. PUBLIC HEALTH RELEVANCE: As of the end of 2007, 33 million people worldwide are infected with HIV. Despite advances in antiretroviral therapies, side-effects and the emergence of viruses resistant to currently available drugs pose important problems for the treatment of HIV. We propose to identify and characterize antiretroviral compounds that block HIV through a novel mechanism. These unique compounds could be used for the treatment of HIV infection.
描述(由申请人提供):多条证据表明,HIV感染细胞中病毒受体的下调是体内调节发病机制的重要功能。我们之前已经进行了概念验证研究,证明干扰这一功能会导致产生不能在允许细胞中复制的非感染性颗粒。在这里,我们建议筛选一个小分子文库来识别CD4下调的抑制剂。我们将使用一种简单的筛选方法来概括生理条件,并使用天然的感染靶细胞。我们提出了以下目标:(1)优化HIV感染的PBMC中CD4下调的检测方法;(2)筛选20,000个类药物化合物的文库;(3)验证和表征HITS的效力、细胞毒性和特异性。将进行研究,以优化筛查条件,减少化验之间的变异性,并进行统计分析,以设定命中鉴定的阈值。假阳性和伪影将在二次检测中被区分,真正的命中化合物将基于效力、特异性和缺乏细胞毒性而被优先排序。将进行初步研究,以验证作用机制,并用实验室适应的艾滋病毒毒株和初级分离株测试这些化合物的抗病毒活性。这一第一阶段应用的成功被定义为里程碑式地鉴定了一个或多个真诚的先导系列类药物化合物,在艾滋病毒复制试验中IC50低于55M,并且细胞毒性最小(CC50是IC50的10倍)。具有这些特征的先导化合物将在第二阶段项目中针对效力、特异性和生物利用度进行优化,旨在推动这些化合物的临床前开发,以支持人体试验。这些研究将构成药物发现计划的基础,该计划可能导致表征一种新型抗逆转录病毒药物家族的一流药物。公共卫生相关性:截至2007年底,全世界有3300万人感染艾滋病毒。尽管抗逆转录病毒疗法取得了进展,但副作用和对现有药物产生抗药性的病毒的出现对艾滋病毒的治疗构成了重要问题。我们建议通过一种新的机制来鉴定和表征能够阻断HIV的抗逆转录病毒化合物。这些独特的化合物可以用于治疗艾滋病毒感染。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JUAN LAMA其他文献

JUAN LAMA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JUAN LAMA', 18)}}的其他基金

Novel Screen to Identify Arenavirus Inhibitors
鉴定沙粒病毒抑制剂的新屏幕
  • 批准号:
    8529177
  • 财政年份:
    2013
  • 资助金额:
    $ 35.63万
  • 项目类别:
Novel Screen to Identify Arenavirus Inhibitors
鉴定沙粒病毒抑制剂的新屏幕
  • 批准号:
    8605165
  • 财政年份:
    2013
  • 资助金额:
    $ 35.63万
  • 项目类别:
Inhibitors of HIV-induced downregulation of HLA class I
HIV 诱导的 I 类 HLA 下调的抑制剂
  • 批准号:
    8410864
  • 财政年份:
    2012
  • 资助金额:
    $ 35.63万
  • 项目类别:
An immune-based approach for HIV eradication
基于免疫的艾滋病毒根除方法
  • 批准号:
    8924889
  • 财政年份:
    2012
  • 资助金额:
    $ 35.63万
  • 项目类别:
An immune-based approach for HIV eradication
基于免疫的艾滋病毒根除方法
  • 批准号:
    9031713
  • 财政年份:
    2012
  • 资助金额:
    $ 35.63万
  • 项目类别:
Inhibitors of HIV-induced downregulation of HLA class I
HIV 诱导的 I 类 HLA 下调的抑制剂
  • 批准号:
    8465183
  • 财政年份:
    2012
  • 资助金额:
    $ 35.63万
  • 项目类别:
An immune-based approach for HIV eradication
基于免疫的艾滋病毒根除方法
  • 批准号:
    9223640
  • 财政年份:
    2012
  • 资助金额:
    $ 35.63万
  • 项目类别:
Targeting HIV-1 Envelope glycoprotein incorporation
靶向 HIV-1 包膜糖蛋白掺入
  • 批准号:
    7685833
  • 财政年份:
    2009
  • 资助金额:
    $ 35.63万
  • 项目类别:
Small-molecule inhibitors of HIV-induced receptor downmodulation
HIV 诱导的受体下调的小分子抑制剂
  • 批准号:
    7754471
  • 财政年份:
    2009
  • 资助金额:
    $ 35.63万
  • 项目类别:
Fusion assay of the HIV-induced CD4 down-modulation
HIV 诱导的 CD4 下调的融合测定
  • 批准号:
    7140590
  • 财政年份:
    2005
  • 资助金额:
    $ 35.63万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 35.63万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.63万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 35.63万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.63万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 35.63万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 35.63万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.63万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 35.63万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 35.63万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.63万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了